Title Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease 2022-08-18

Publication in Nature Molecular Psychiatry Supports Genuv’s Alternate Theory for Treatment of Alzheimer’s Disease

Article in peer-reviewed publication provides validation of Genuv’s novel neuroprotection approach to Alzheimer’s disease

SEOUL, Republic of Korea--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody therapies for immuno-oncology, announced the publication of a manuscript in Molecular Psychiatrya peer-reviewed scientific journal published by Springer Nature Group. The new research provides important validation for the company’s six-year effort to develop new treatments for neurodegenerative diseases including Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).



To view original article, please click here.


Next Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier